NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
LYRICA CR (pregabalin) by Viatris (2) is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. First approved in 2017.
Drug data last refreshed 9h ago · AI intelligence enriched 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA CR is an extended-release formulation of pregabalin, a small-molecule CNS agent that binds to the alpha-2-delta subunit of voltage-gated calcium channels to reduce pro-nociceptive neurotransmitter release. It is indicated for neuropathic pain and other chronic pain conditions, working through modulation of calcium-dependent signaling and descending pain pathways rather than direct GABA or opioid receptor activity. The mechanism involves reducing calcium currents in nerve damage models and potentiating descending noradrenergic and serotonergic pain control pathways.
$0.4MPart D
LOE Approaching9mo to LOELYRICA CR is in late-stage lifecycle with patent exclusivity expiring May 2027 and a small Part D footprint, signaling a consolidation phase likely characterized by defensive positioning and reduced commercial headcount.
Mechanism of Action
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA CR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.